Bruker launches timsUltra AIP workflow to boost protein sequence coverage in proteomics studies

By Public Technologies
  • Bruker unveiled new timsUltra AIP and timsOmni workflows aimed at deeper proteomics coverage, targeted validation, glycoproteomics, structural proteomics, oligonucleotide analysis.
  • Multi-enzyme dia-PASEF on timsUltra AIP produced about 350,000 peptides per Parkinson’s brain sample, supporting about 14,500 isoforms.
  • ProteoScape adds a discovery-to-validation path that converts PASEF discovery outputs into prm-PASEF target lists on the same timsTOF platform.
  • Spectronaut v21 transfer learning is positioned to speed AI model adaptation to new acquisition modes without rebuilding models from scratch.
  • timsOmni workflows added mobility-resolved glycopeptide characterization above 30 Hz, HDX-MS integration, EDD-MS3 to reach complete RNA and DNA oligonucleotide coverage.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bruker Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202609280700BIZWIRE_USPR_____20260928_BW599979) on September 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.